Non-Invasive Diagnostics (NITs)
Health Canada has issued updated guidance recommending the universal use of non-invasive tests (NITs) for adults at high risk of MASLD. The transition away from liver biopsies toward FIB-4 scores and transient elastography is intended to improve patient compliance and early detection. View the PHAC Liver Disease portal for technical details.
Managing Metabolic Risk
Early screening is vital for reversing fibrosis before it reaches the cirrhotic stage. Canadian clinicians are encouraged to integrate these tests into annual check-ups for patients with metabolic syndrome, heart health concerns, or Type 2 diabetes.
Improving Hepatology Outcomes Across Provinces
The 2026 Health Canada framework addresses the rising incidence of NASH (now MASLD) by standardizing diagnostic thresholds. By lowering the cost and risk of screening, the goal is to identify patients who would benefit from aggressive weight reversal or new pharmacological interventions. This proactive approach is expected to reduce the future burden on Canada's liver transplant waitlists.
Elastography and Shear Wave Velocity
Transient elastography measures liver stiffness by sending a mechanical pulse. The stiffness ($E$) is related to the shear wave velocity ($c_s$) and tissue density ($\rho$): $$E = 3 \rho c_s^2$$. Higher $E$ values (in kPa) correlate with more advanced stages of fibrosis, allowing for a precise, non-invasive assessment of chronic liver disease progression.
Authoritative Support
The Canadian Liver Foundation provides patient resources for understanding test results. Additionally, CADTH has published an evidence-based review on the cost-utility of routine elastography in primary care, supporting the wider implementation of these metabolic health standards.